Patch test results from the Mayo Clinic Contact Dermatitis Group, 1998-2000 - 21/08/11
Correspondence to: Mark D. P. Davis, MD, Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.Rochester, Minnesota; Scottsdale, Arizona; and Jacksonville, Florida
Abstract |
Background |
Patch testing is a diagnostic tool for the evaluation of patients with suspected allergic contact dermatitis. A standard series of allergens similar to that used by the North American Contact Dermatitis Group (NACDG) is used at Mayo Clinic.
Objective |
Our aim was to report the results of patch testing with a standard series at Mayo Clinic from July 1, 1998, to Dec 31, 2000 and to compare our findings with those of the NACDG during the same period.
Methods |
The results of patch testing with the standard series at Mayo Clinic were examined. Positive reaction rates were compared between Mayo Clinic and the NACDG.
Results |
During the 30-month period, 1324 Mayo Clinic patients were patch tested with a standard series of allergens (mean, 60 allergens), whereas the NACDG standard series during this period included 50 allergens. Overall, 917 patients (69.3%) had at least one positive reaction and 606 patients (45.8%) had two or more positive reactions. The 10 allergens used both by Mayo Clinic and by the NACDG that most frequently caused positive reactions were nickel sulfate hexahydrate, balsam of Peru (Myroxylon pereirae), neomycin sulfate, cobalt chloride, fragrance mix, potassium dichromate (0.25%), thimerosal, bacitracin, formaldehyde, and glutaraldehyde. Statistically significant differences in positive reaction rates (P < .05) were observed for 12 of the 43 allergens common to both Mayo Clinic and the NACDG.
Conclusion |
With large standard patch test series, one can identify commonly encountered and potentially relevant contact allergens.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. Conflicts of interest: None. Reprints not available from the authors. |
Vol 53 - N° 3
P. 416-421 - septembre 2005 Retour au numéro
Article précédent
- Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases
- Timothy R. Coté, Aparna K. Mohan, Jacquelyn A. Polder, Marc K. Walton, M. Miles Braun
- The role of cytotoxic skin-homing CD8+ lymphocytes in cutaneous cytotoxic T-cell lymphoma and pityriasis lichenoides
- Joerg Wenzel, Ines Gütgemann, Moritz Distelmaier, Manfred Uerlich, Sandra Mikus, Thomas Bieber, Thomas Tüting
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?